Phase i study of on 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies

Leukemia

Volumn 27, Issue 9, 2013, Pages 1920-1923

  Roschewski, M ^a,b   Farooqui, M ^b   Aue, G ^b   Wilhelm, F ^c   Wiestner, A ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c Onconova Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CYTOCHROME C; ON 01910NA; PHOSPHATIDYLINOSITOL 3 KINASE; RIGOSERTIB; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CATHETER THROMBOSIS; CELL CYCLE PROGRESSION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FAINTNESS; FEMALE; HAIRY CELL LEUKEMIA; HUMAN; INFECTION; INFUSION PUMP; LETTER; LYMPHOMA; MALE; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MITOSIS INHIBITION; MULTIPLE MYELOMA; MUSCULOSKELETAL PAIN; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OXIDATIVE STRESS; PERIPHERALLY INSERTED CENTRAL VENOUS CATHETER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SALVAGE THERAPY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FEMALE; GLYCINE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; RECURRENCE; SULFONES; TREATMENT OUTCOME;

EID: 84883739917     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.79     Document Type: Letter

References (14)

1. Reddy MV, Mallireddigari MR, Cosenza SC, Pallela VR, Iqbal NM, Robell KA et al. Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents. J Med Chem 2008; 51: 86-100.
2. Reddy MV, Venkatapuram P, Mallireddigari MR, Pallela VR, Cosenza SC, Robell KA et al. Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-Methoxy-5-[(20,40,60-trimethoxystyrylsulfonyl)methyl]phenylamino} acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity. J Med Chem 2011; 54: 6254-6276.
3. Prasad A, Park IW, Allen H, Zhang X, Reddy MV, Boominathan R et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene 2009; 28: 1518-1528.
4. Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005; 7: 275-286. (Pubitemid 40568686)
5. Lenart P, Petronczki M, Steegmaier M, Di Fiore B, Lipp JJ, Hoffmann M et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007; 17: 304-315.
6. Oussenko IA, Holland JF, Reddy EP, Ohnuma T. Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation. Cancer Res 2011; 71: 4968-4976.
7. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M et al. Phase I Study of ON 01910.Na, a novel modulator of the polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008; 26: 5504-5510.
8. Olnes MJ, Shenoy A, Weinstein B, Pfannes L, Loeliger K, Tucker Z et al. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res 2012; 36: 982-989.
9. Seetharam M, Fan AC, Tran M, Xu L, Renschler JP, Felsher DW et al. Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res 2012; 36: 98-103.
10. Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L et al. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res 2012; 18: 1979-1991.
11. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
12. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23: 3-9.
13. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586. (Pubitemid 350002966)
14. Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C et al. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clin Cancer Res 2012; 18: 2048-2055.